Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

A spiro-compound, including pharmaceutically acceptable salts thereof, enantiomers and racemates thereof and quaternary compounds derived therefrom when said compound has a tertiary nitrogen atom, wherein said spiro-compound contains a five-membered moiety in which a spiro-junction exists at a carbon atom thereof and simultaneously at a carbon atom of a saturated ring system containing one nitrogen atom, wherein said five-membered moiety is selected from the group consisting of 3-ethylhydantoin, 1-acetylhydantoin, 3-methylhydantoin, 3-propargylhydantoin, 2,4-dithiohydantoin, 2-thiohydantoin, oxazolidine-2-thione, 3-ethyloxazolidine-2-one, oxazolidine-2,4-dione, 3-ethyloxazolidine-2,4-dione, 2-methyl-1,4-oxazolidine-3-one, 2-methyl-1,4-thiazolidine-3-one, 2,4-dimethyl-1,4-thiazolidine-3-one, 2-ethyl-1,4-thiazolidine-3-one, 2-ethyl-1,4-thiazolidine-3-one, 2-methyl-3-oxo-1,4-thiazolidine-1-oxide, 5-methyl-1,3-dioxolane-4-one, N-methylsuccinimide, N-ethyl-succinimide, 3-t-butylhydantoin, 3-(4-pyrrolidino-2-butynyl)hydantoin, 3-(2-butynyl)-hydantoin, 2,5-bis(methylthio)-1H-imidazole, 3-ethyl-4-thiohydantoin, 4-methylthioimidazoline-2-thione, 3-ethyl-2,4-dithiohydantoin, 4-ethylthio-3-imidazoline-2-thione, 1-ethyl-2-ethylthio-2-imidazoline-5-thione, 2-thio-4.beta.-hydroxyethyliminohydantoin, 2,5-bis(aminomethyl)-4H-imidazole, 2-methyl-2-thiazoline, 2-methyl-2-imidazoline, 2-methyl-2-oxazoline-4-one, 2-methyl-4H(5H)-imidazole-5(4)-one, 2-methylthio-5-methoxy-4H-imidazole, 2-methylthio-5-amino-4H-imidazole, 2-methylthio-5-aminomethyl-4H-imidazole, 2-thione-3-ethylhydantoin, 2-thione-3-t-butylhydantoin, 2-methylthio-2-imidazoline-5(4)-one), 1-ethyl-2-ethylthio-2-imidazoline-5-one and 1-ethyl-2-imidazoline-5-one;

• and wherein said saturated ring system containing one nitrogen atom is selected from the group consisting of moieties K, L, M, N and P:
• ##STR21## wherein each such moiety is unsubstituted or substituted by 1-3 substituents selected from C.sub.1-6 alkyl and hydroxyl;
• wherein the bridge in structures K and L is attached at one end to position 1 and at the other end to position 4 or 5;
• wherein m is 1, 2 or 3, and n and p are each independently 0, 1, 2, or 3, provided that n+p=1-3;
• wherein R.sup.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl, C.sub.2-6 -alkynyl, C.sub.3-7 -cycloalkyl, C.sub.1-6 -alkyl substituted by 1-6 halogen atoms, hydroxy-C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy, C.sub.1-6 alkylthio, C.sub.1-6 alkyl, carboxy-C.sub.1-6 alkyl, (C.sub.1-6 alkoxy)carbonyl-C.sub.1-6 alkyl, amino-C.sub.1-6 -alkyl, mono(C.sub.1-6 -alkyl) amino C.sub.1-6 -alkyl, di-C.sub.1-6 -alkyl, 2-oxo-pyrrolidin-1-yl-methyl, aryl, diarylmethylol, C.sub.1-6 -alkyl substituted by one or two aryl groups C -alkanoyl or arylcarbonyl;
• wherein aryl is phenyl or phenyl substituted by 1-3 substituents selected from the group consisting of halogen, C.sub.1-6 -alkyl, C.sub.1-6 -alkoxy and CF.sub.3 ;
• and wherein R.sup.2 and R.sup.3 are independently C.sub.1-4 alkyl;
• wherein when said saturated ring system is M, n is 1, p is 1 and R.sup.1 is hydrogen or methyl, said five-membered moiety is not 3-ethylhydantoin, 1-acetylhydantoin, 3-methylhydantoin, 3-propargylhydantoin, 2,4-dithiohydantoin, 2-thiohydantoin, oxazolidine-2-thione, 3-ethyloxazolidine-2-one, 3-ethyl-4-thiohydantoin, 4-methylthiomidazoline-2-thione, 3-ethyl-2,4-dithiohydantoin, 4-ethylthio-3-imidazoline-2-thione, 1-ethyl-2-ethylthio-2-imidazoline-5-thione, 2-thio-4.beta.-hydroxyethyliminohydantoin, 2-methyl-2-thiazoline, 2-methyl-2-imidazoline, 2-methyl-2-oxazoline-4-one.